Scotland’s NICE dislikes GSK’s Anoro

The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.

August 11, 2014

5:54 pm

Scotland’s version of NICE, the Scottish Medicines Consortium (SMC), says two COPD drugs are not worth the Scottish National Health Service’s money.

Among the drugs Regulatory Focus found on the SMC’s “not recommended” list were GlaxoSmithKline’s Anoro (umeclidinium/vilantero) and Boehringer Ingelheim’s Striverdi Respimat (olodaterol).

From Our Partners

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.